Compare WBX & MDXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WBX | MDXH |
|---|---|---|
| Founded | 2015 | 2003 |
| Country | Spain | Belgium |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 65.2M | 68.7M |
| IPO Year | 2021 | 2021 |
| Metric | WBX | MDXH |
|---|---|---|
| Price | $3.12 | $0.62 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 3 |
| Target Price | $4.75 | ★ $7.67 |
| AVG Volume (30 Days) | 10.2K | ★ 238.6K |
| Earning Date | 05-06-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $18.10 | $30.78 |
| Revenue Next Year | $94.11 | $18.31 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.30 | $0.40 |
| 52 Week High | $7.83 | $5.33 |
| Indicator | WBX | MDXH |
|---|---|---|
| Relative Strength Index (RSI) | 45.72 | 45.51 |
| Support Level | $2.77 | $0.51 |
| Resistance Level | $3.19 | $0.75 |
| Average True Range (ATR) | 0.18 | 0.04 |
| MACD | 0.01 | -0.02 |
| Stochastic Oscillator | 19.87 | 7.49 |
Wallbox NV is a smart electric vehicle charging and energy management company. It creates a smart charging system combining technology design that manages the communication between the user, vehicle, grid, building, and charger. The company designs, manufactures, and distributes faster, simpler EV charging solutions for residential, business, and public use. Its smart charging product portfolio includes Level 2 alternating current chargers for home and business applications and direct current fast chargers for public applications. The company has three reportable operating segments: Europe, the Middle East and Asia (EMEA), its key revenue-generating segment, North America, and Asia-Pacific.
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.